1. Wittchen HU. Generalized Anxiety Disorder. Prevalence Burden, and Cost to Society. Depress Anxiety 2002; 16: 162–71.
2. Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602.
3. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617–27.
4. Greenberg PE, Sisitky T, Kessler RC et al. The economic burden of anxiety disorders n the 1990s. J Clin Psychiatry 1999; 60: 427–35.
5. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington: Am Psychiatric Assoc 2001. Am Psychiatric Assoc. DSM-IV-TR.
6. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 355–64.
7. Olfson M, Fireman B, Weissman MM et al. Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry 1997; 154: 1734–40.
8. Brawman-Mintzer O, Lydiard RB. Generalized anxiety disorder: Issues in epidemiology. J Clin Psychiatry 1996; 57(Suppl. 7): 3–8.
9. Berger A, Edelsberg J, Bollu V et al. Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study. BMC Psychiatry 2011; 11: 193.
10. Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the Br Assoc Psychopharmacol. J Psychopharmacol 2005; 19: 567–96.
11. Gorman JM. Treating generalized anxiety disorder. J Clin Psychiatry 2003; 64(Suppl. 2): 24–9.
12. Lader M. Effectiveness of benzodiazepines: Do they work or not? Exp Rev Neurother 2008; 8: 1189–91.
13. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988; 49 (8): 293–301.
14. Rickels K, Downing R, Schweizer E et al. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50(11): 884–95.
15. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005; 66 (10): 1321–5.
16. Katzman MA, Vermani M, Jacobs L et al. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 2008; 22 (8): 1480–6.
17. Bandelow B, Chouinard G, Bobes J et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder: data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010; 13 (3): 305–20.
18. Swartz CM. Betaxolol in anxiety disorders. Ann Clin Psychiatry 1998; 10 (1): 9–14.
19. Darcis T, Ferreri M, Natens J et al. The French GP Study Group for Hydroxyzine. A multicentre double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety. Hum Psychopharmacol 1995; 10 (3): 181–7.
20. Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl) 1998; 139 (4): 402–6.
21. Аведисова А.С. и др. Новый анксиолитик Афобазол при терапии ГТР (результаты сравнительного исследования с диазепамом). Психиатрия и психофармакотерапия. Журн. им. П.Б. Ганнушкина. Эктравыпуск. 2006; с. 13–6.
22. Смулевич А.Б. и др. Терапия пограничных психических расстройств (исследование эффективности и переносимости Афобазола). Психиатрия и психофармакотерапия. Журн. им. П.Б. Ганнушкина. Эктравыпуск. 2006; с. 3–9.
23. Акарачкова Е.С., Шварков С.Б., Мамий В.И. Афобазол в терапии тревожных расстройств. Лечение нервных болезней. 2007; 1: 4–7.
24. Mathew SJ, Price RB, Mao X et al. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry 2008; 63 (9): 891–8.
25. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 1998; 155 (7): 992–3.
26. Schaller JL, Thomas J, Rawlings D. Low-dose tiagabine effectiveness in anxiety disorders. MedGenMed 2004; 6 (3): 8.
27. Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160 (3): 533–40.
28. Lydiard RB, Rickels K, Herman B et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010; 13 (2): 229–41.
29. Aliyev NA, Aliyev ZN. Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry 2008; 23 (2): 109–14.

О.В.Котова

Отдел патологии вегетативной нервной системы НИЦ Первого МГМУ им. И.М.Сеченова